You are here

Drug Use Evaluation of Moxifloxacin (Avelox) Using a Hand-Held Electronic Device At a Canadian Teaching Hospital

Jennifer A. E. Samilski MD
Tim T. Y. Lau PharmD, ACPR
Dean H. T. Elbe PharmD, ACPR, BCPP
Amneet K. Aulakh PharmD, ACPR


The use of moxifloxacin (Avelox) has increased at Vancouver General Hospital since its introduction onto the formulary in 2002. It is unclear, however, whether the use of the drug is optimal according to its indication. Hand-held electronic devices, such as personal digital assistants (PDAs), are novel tools that can be used during routine patient care to collect data for drug use evaluation (DUE) reviews.


We hypothesized that moxifloxacin was over-utilized and that opportunities existed to optimize its use. This study was designed to characterize moxifloxacin use in concordance with evidence-based assessment criteria. The feasibility of using a PDA device as a data-collection tool was also evaluated.


An observational DUE was conducted over a 4-week period (from February 17 to March 16, 2007) at Vancouver General Hospital, a 955-bed tertiary care hospital. Inpatients who received at least one dose of moxifloxacin were enrolled. Evidence-based assessment criteria were developed to evaluate the appropriateness of moxifloxacin use, and a PDA database was developed for data collection. The primary endpoint was the proportion of moxifloxacin use for approved first-line indications.


A total of 132 patients were included. Eighty-nine patients (67%) received moxifloxacin for first-line indications, including community-acquired pneumonia (57%) and acute exacerbation of chronic bronchitis (10%). Forty-three patients (33%) had alternative indications, primarily hospital-acquired pneumonia (25%). In 129 evaluable patients, approximately half (51%) of the clinical outcomes were successful; 37% were indeterminate; and 12% were failures. General medicine and respiratory service clinicians prescribed moxifloxacin more appropriately compared with surgical service personnel. Most of the pharmacists supported the use of PDAs as DUE data-collection tools.


Overall, moxifloxacin utilization at Vancouver General Hospital was appropriate according to evidence-based assessment criteria. Additional opportunities to improve its use exist through health care staff education. PDAs are ideal data-collection tools for DUEs, as they can be conveniently used during routine patient care.



Moxifloxacin (Avelox, Bayer) is a fluoroquinolone antibiotic with activity against respiratory pathogens. In Canada, moxifloxacin is approved for the treatment of acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS), community-acquired pneumonia (CAP), complicated intra-abdominal infections (IAIs), and complicated skin and skin structure infections (SSSIs).1,2

At Vancouver General Hospital, moxifloxacin use has increased since its addition to the formulary in 2002, when it replaced levofloxacin (Levaquin, Ortho-McNeil/Janssen). During fiscal year 2009–2010, the cost of moxifloxacin exceeded $200,000 (in Canadian dollars), accounting for approximately 5% of the total annual anti-infective expenditures of $4 million. In previous studies of fluoroquinolones, high rates of suboptimal use (from 31% to 81%) had been reported.310 The utilization characteristics of moxifloxacin had not been formally assessed at our institution, and it was unclear whether its use was optimal based on its therapeutic indication.

Drug Use Evaluation

Drug use evaluation (DUE) is a systematic approach that assesses the appropriateness, safety, and effectiveness of a medication to improve patient care.11 Optimizing medication utilization has the potential to reduce the development of antimicrobial resistance and to lower overall health care costs by providing cost-effective treatments.11 Traditionally, DUEs have involved paper-based, retrospective reviews of patient health records. This method is labor-intensive and inefficient, because information is manually retrieved, reviewed, and reentered into an electronic format. Other drawbacks include the potential for missing information and an overreliance on the investigators’ interpretation of archived data. In addition, results from retrospective DUEs might not reflect the drug’s current usage.

Personal Digital Assistants

Compared with paper-based systems, hand-held electronic devices or personal digital assistants (PDAs), when used to conduct DUEs during routine patient care, represent a novel approach that offers several advantages. Data are more recent and complete, and they can be captured with greater efficiency into a readily analyzable electronic format. Prospective data may also be more robust than a retrospective review, because PDA users have the opportunity to clarify data in patients’ medical records with health care practitioners. Only a few studies have assessed the utility of PDAs as data-collection tools for DUEs.12

Hypothesis and Objective

We hypothesized that moxifloxacin was being overutilized at Vancouver General Hospital and that opportunities existed to optimize its use. Accordingly, our study aimed to characterize moxifloxacin use at our institution in concordance with evidence-based assessment criteria. We also evaluated the feasibility of PDAs as data-collection tools.


Design and Site

Our observational, retrospective DUE was conducted at Vancouver General Hospital, a 955-bed, tertiary-care, university-affiliated teaching facility in Vancouver, British Columbia, Canada. Ethics and research approvals were granted by the Clinical Research Ethics Board of the University of British Columbia and by the Vancouver Coastal Health Research Institute. We conducted the study over a 4-week period, from February 17 to March 16, 2007. Patients who received at least one dose of moxifloxacin in an acute inpatient ward were enrolled.

Development of Assessment Criteria

Evidence-based assessment criteria were developed to evaluate the appropriateness of moxifloxacin use. We performed a literature search of Medline, EMBASE, and PubMed from 1966 to November 2006 using the search term “moxifloxacin” with predefined search filters.13 We identified and reviewed a total of 1,023 citations, yielding 74 relevant citations (37 randomized controlled trials, 24 cohort or observational studies, seven case reports, three systematic reviews, and three practice guidelines).

Relevant articles were sorted by therapeutic indication and were classified according to the Infectious Diseases Society of America (IDSA) grading system to create three “levels of evidence” criteria14 (Table 1).

After levels of evidence were established for each therapeutic indication, we determined the “place of therapy” for moxifloxacin use at our institution (see Table 1). We classified moxifloxacin as a first-line therapy when it was considered the agent of choice and as an alternative therapy when it was a therapeutic alternative to a first-line agent. The place of therapy for the various indications was endorsed by the Antibiotic Use Subcommittee at Vancouver General Hospital and was based on local standards of practice, the hospital’s drug formulary, preprinted physician orders, antibiotic susceptibility patterns, and the opinion of experts in infectious diseases.

Development of the PDA Database

We developed the PDA database using Pendragon Forms (version 3.2). Palm Pilot Tungsten E/E2 models running Palm Operating System 5 were used for data collection. Data were collected on a single Pendragon Forms page. We entered the data fields using:

  • free text, which included patients’ initials; study subject number; antibiotic allergies; comorbidities; concomitant use of oral medications; significant adverse drug effects; and therapeutic indications.
  • drop-down lists, which included:
  • ○ clinical outcome achieved: success, indeterminate, or failure.
  • ○ route of therapy.
  • ○ type of therapy: directed, empirical, or prophylactic.

The PDA data that the clinical pharmacists collected were synchronized via a hard-wired connection to Pendragon Forms over the hospital network to a central server in the Department of Pharmaceutical Sciences. The frequency of synchronization by clinical pharmacists was variable, but data collection was completed before the end of the 4-week study period.

To maintain patient confidentiality, both the PDA and the Pendragon Forms software on the hand-held device were password-protected. The Department of Pharmaceutical Sciences and the Vancouver Coastal Health Research Institute considered this step to be adequate in protecting patient information.

Participating pharmacists were enrolled in a training session and received an information handout. A pilot test of data collection was performed by J.A.E.S. and D.H.T.E. over a 1-week period before study enrollment.

Data Collection

We identified patients from a pharmacy computer-system target drug report, which documented all patients who had started moxifloxacin the previous day. Clinical pharmacists performed data collection using PDAs during routine patient care, which was defined as providing pharmaceutical care activities in the wards and during patient rounds.

Patients were observed until the completion of therapy or hospital discharge. The pharmacy computer system was also used to identify patients who received moxifloxacin but who were not observed prospectively by clinical pharmacists during routine care.

Because of limited pharmacy resources and logistical problems, the pharmacists did not observe all inpatients. To provide a representative summary of moxifloxacin use from this second group, we collected data retrospectively from a random sample of paper-based medical records using a PDA. We documented the time required to collect these data. We collected data from non-computerized sources (e.g., information during routine care and paper-based medical records) and from the hospital patient-care information system (PCIS).

Noncomputerized data consisted of antibiotic allergies, outcomes (i.e., success, indeterminate, or failure), comorbidities, concomitant use of oral medications, route of administration, moxifloxacin adverse effects, therapeutic indications, and type of therapy (directed, empirical, or prophylactic). Using PDAs, clinical pharmacists collected the data during routine patient care.

Data collected from the PCIS included patient demographics (i.e., age, sex, admitting service, hospital ward, physician, and length of stay), medication use (i.e., dose, route of administration, and duration), and concomitant antibiotics. We extracted the data by synchronizing the PDAs to the database.

The final database was built in Microsoft Access 2003. Patients’ records were exported from Pendragon Forms to Microsoft Access 2003 to allow the merging of these data with extracted data from the hospital’s PCIS.


The following terms were used to assess moxifloxacin utilization:

Type of therapy. Moxifloxacin treatment was defined as “directed” therapy when it was initiated based on culture and sensitivity results that targeted a known pathogen; as “empirical” therapy when the drug was initiated based on expected pathogens or on pending culture and sensitivity results; and as “prophylactic” therapy when it was used to prevent infection.

Clinical outcomes. Outcomes were assessed for all patients and were defined as follows:

  • Success: Patients experienced (1) complete resolution of signs and symptoms of infection (improvement of all baseline parameters in the hospital or at discharge) or (2) significantly fewer signs and symptoms.
  • Indeterminate: It was not possible to evaluate the patient’s health status because of insufficient data (e.g., if a patient was discharged without clarification of his or her status).
  • Failure: Patients experienced (1) persistent or worsening signs and symptoms of infection, requiring the initiation of an alternative anti-infective agent, or (2) no significant remission of signs and symptoms (no improvement in baseline parameters).

Serious adverse drug effects. Adverse effects referred to any untoward occurrence resulting from moxifloxacin that necessitated a change in therapy.

Study Endpoints and Survey

The primary endpoint was the proportion of moxifloxacin use in approved first-line indications compared with alternative indications. Secondary endpoints included:

  • the proportion of successful, indeterminate, or failure outcomes achieved with the use of moxifloxacin as first-line therapy compared with its use as an alternative therapy.
  • the type of therapy (directed, empirical, or prophylactic) and its clinical outcomes.
  • the proportion of level II and III evidence utilization according to prescribing medical services.
  • the duration of moxifloxacin therapy by indication.
  • the proportion of patients receiving IV moxifloxacin and concomitant oral medications whose regimen was stepped down from IV to oral moxifloxacin.
  • the incidence of serious adverse drug effects.
  • satisfaction with PDAs as DUE data-collection tools.

To assess the utility of the PDA as a DUE data-collection tool, we sent a survey to all participating clinical pharmacists at the completion of the data-collection period.

Statistical Analysis

We performed descriptive statistical analyses using Microsoft Office Excel 2003.



We identified a total of 202 eligible patients. Pharmacists entered 136 records into the PDA database during routine patient care. We excluded 30 records for the following reasons: 18 patients received moxifloxacin outside of the study period; eight records were duplicate entries; and four records were incomplete. Thus, 106 completed records were included in the study (Figure 1). In an effort to collect representative data from the 96 patients who were not followed by clinical pharmacists, we randomly selected a convenience sample of 26 patients and collected data via a retrospective review of health care records. A total of 132 patients were included in the final analysis.

Patient Demographics

Demographic characteristics are listed in Table 2. Median patient age was 73 years (range, 20–100 years). Most patients (69%) did not have drug allergies. The most common co-morbidity was respiratory disease (asthma or chronic obstructive pulmonary disease [COPD]), which was present in 30% of patients. Other comorbidities included an immunocompromised state (in 28%) and hospitalization more than 48 hours before pneumonia (in 27%). Moxifloxacin therapy was initiated predominantly by the general medicine, respiratory, and surgical services.

Primary Endpoint

Indications for moxifloxacin are summarized in Figure 2. Of the 132 patients in this study, 89 (67%) received moxifloxacin as a first-line therapy. Seventy-five patients (57%) were treated with first-line moxifloxacin for CAP, and the remaining 13 patients (10%) were treated for AECB. Forty-three patients (33%) received moxifloxacin as an alternative therapy for a variety of diseases, and hospital-acquired pneumonia (HAP) was the most common disease (25%). Other indications for alternative therapy included empyema, malignant pleural effusion, postoperative pulmonary surgery, tuberculosis, intra-abdominal infections, acute bacterial sinusitis, and SSSIs.

Secondary Endpoints

Outcomes. Outcome analyses were completed for 129 of the 132 patients. In this cohort, 51% of the clinical outcomes were successful, 37% were indeterminate, and 12% were failures. When moxifloxacin was used for approved indications as first-line therapy, successful outcomes were achieved in 49 of 85 patients (58%) (Figure 3). By contrast, when moxifloxacin was used as alternative therapy (mainly for HAP), the outcomes were considered indeterminate in 22 of 44 patients (50%).

Type of therapy. The use of moxifloxacin was empirical in 111 of the 129 patients (86%). Directed moxifloxacin therapy was provided in 17 patients (13%) and was successful in 12 of these patients (69%). Only one patient (less than 1%) received prophylactic treatment.

Service. According to Level I evidence, moxifloxacin was usually prescribed appropriately by general medicine and respiratory services in 45 of 50 patients (90%) and in 21 of 26 patients (81%), respectively. According to Level III evidence, moxifloxacin was used more often in the surgical wards (Figure 4).

Duration of therapy. The median duration of treatment for CAP and AECB was 7 days (Table 3). The duration of therapy for HAP was slightly shorter (a median of 6 days). Durations for other indications ranged from 5 to 8 days, except for tuberculosis (a median of 22 days).

IV-to-oral step-down therapy. Of the 132 patients, 75 (57%) received IV moxifloxacin; 39 patients (30%) received IV moxifloxacin while concomitantly receiving oral medications. Of these 39 patients, 22 (56%) were given step-down treatment to oral moxifloxacin. The remaining 17 patients (44%) continued with IV moxifloxacin for the duration of treatment.

Adverse drug-related effects. Two patients experienced significant adverse events, resulting in the replacement of moxifloxacin with a therapeutic alternative. In one patient, a maculopapular, erythematous rash improved when moxifloxacin was discontinued. The second patient experienced severe diarrhea, which was associated with the initiation of moxifloxacin; no documentation of improvement was available for this patient.

PDA utility survey. Nine of 13 pharmacists (69%) completed the PDA utility survey (Table 4). Overall, most of the pharmacists supported the use of PDAs as DUE data-collection tools. Six of the nine responding pharmacists (67%) stated that the PDA program was easy to use and did not adversely affect their ability to deliver patient care. Five pharmacists (56%) indicated that they would take part in future PDA-based data-collection studies. On average, the time required for data entry was 4 minutes (range, 2–7 minutes) per patient. In contrast, the average time required to complete data collection via a retrospective chart review was 28 minutes (range, 8–47 minutes) per chart.


Our goal was to determine the appropriateness of moxifloxacin use at the Vancouver General Hospital and to assess the utility of PDAs as data-collection tools. To our knowledge, this is the only published DUE study of moxifloxacin using evidence-based assessment criteria in accordance with the IDSA’s levels of evidence grading system in which PDAs are being used as data-collection devices.12

Moxifloxacin DUE

In this study, moxifloxacin utilization was appropriate in 89 of 132 patients (67%) and was concordant with evidence-based assessment criteria. The two most common first-line indications were CAP and AECB. Clinical results with moxifloxacin were suboptimal in 43 patients (33%); most of these patients had HAP. These results are consistent with previous fluoroquinolone DUEs, which reported inappropriate usage in 31% to 81% of patients.37,10 Similarly, Belliveau et al., reviewing the use of levofloxacin at an academic teaching institution, determined that its usage was justified only 53.9% of the time.9

Moxifloxacin is active against respiratory pathogens in CAP and AECB, as supported by Level I evidence from clinical trials and by IDSA practice guidelines.1527 Consequently, moxifloxacin is used extensively at our institution as a primary agent for respiratory infections and is strongly concordant with our assessment criteria. Other possible explanations for the high rate of appropriate use of moxifloxacin include the availability of preprinted physician orders for AECB at our institution, where moxifloxacin is one of the first-line treatment options, and the interventions of clinical pharmacists during daily inpatient medical rounds.

Most of the inappropriate use of moxifloxacin was for HAP, the second most common indication. The role of moxifloxacin in the treatment of HAP is controversial. In clinical practice guidelines from the IDSA and the American Thoracic Society, moxifloxacin is an empirical option for HAP patients who are not at risk for multidrug-resistant organisms.28 However, during our literature search, we did not find Level I support for the use of moxifloxacin in these patients, and moxifloxacin has not been approved for this indication.

Because moxifloxacin is widely used for community-associated respiratory infections, it is important to restrict its use for indications that have the most literature support and benefit in order to reduce its overuse and its potential for resistance. Based on this premise, our Antibiotic Use Subcommittee classified moxifloxacin as an alternative therapy for HAP.

Although moxifloxacin is approved for patients with acute bacterial sinusitis,29,30 SSSIs,31,32 and complicated IAIs,33,34 its use for these indications is minimal. Despite Level I support, our institution has categorized moxifloxacin as an alternative agent for these conditions. The rationale for this decision was the availability of other formulary alternative agents for these infections as well as the need to prevent moxifloxacin overuse and resistance, because moxifloxacin was already used extensively for community-associated respiratory infections. In addition, the “place of therapy” for moxifloxacin was determined based on the level of evidence and other considerations, such as local standards of practice, antibiotic resistance patterns, and the opinion of experts in infectious diseases.3538

Successful clinical outcomes were achieved more frequently with first-line moxifloxacin in contrast to its use as alternative therapy. More successful outcomes were achieved in patients with CAP (39 of 71 patients; 55%) than in those with HAP (11 of 33 patients; 33%). In both indications, successful outcomes were more likely when moxifloxacin was targeted at a known pathogen rather than when it was used empirically. Overall, moxifloxacin was mostly used for the empirical treatment of CAP.

Clinical failures occurred in patients with CAP, HAP, and AECB. In CAP, 10 of 71 patients (14%) experienced clinical failures; this rate was similar to rates reported in other clinical studies.2024 The failure rate in patients with HAP was difficult to interpret, because the outcomes were indeterminate for 17 of 33 patients (52%). Possible reasons included the loss of patients to follow-up because of transfers to other medical wards that were not covered by clinical pharmacists and discharge from the hospital. Of 14 patients with AECB, one patient (7%) did not respond to moxifloxacin; this failure rate was comparable with rates in other trials.1519

The medicine and respiratory services prescribed moxifloxacin appropriately in 90% of cases, based on Level I evidence. In contrast, surgical services (cardiovascular, orthopedics, thoracics, and general surgery) used moxifloxacin for non-recommended indications, mostly in patients with HAP. These findings suggest that there is a need for educating the surgical groups on the appropriate use of moxifloxacin. Overall, the median duration of treatment for CAP and AECB was appropriate.

The overuse of IV moxifloxacin was a concern. Thirty-nine patients who received IV moxifloxacin were eligible for oral therapy. Of these patients, 17 (44%) continued with IV moxifloxacin while they also received oral medications concomitantly. These findings are parallel to those of other fluoroquinolone studies, in which suboptimal use was reported in patients who continued on IV therapy despite having no contraindications to oral therapy.4,8 Because moxifloxacin has high bioavailability (90%), the oral form is the preferred route unless oral absorption or a drug interaction is a concern.2,4,6,10

To promote the appropriate use of moxifloxacin, clinicians should adopt strategies aimed at affecting prescribing behavior. These strategies include individual physician prescribing feedback, multidisciplinary in-services that collaborate with infectious-disease physicians, and prescriber education through academic detailing.4,7,39 Based on the results of our study, emphasis should be placed on educating surgical services groups.

The pharmacist-managed, IV-to-oral dosage-form conversion service at our institution should be reinforced to optimize the oral administration of moxifloxacin and to minimize costs. This approach should be used in conjunction with other established methods, including newsletters, chart talkers, notes, and direct pharmacist–physician interactions.4,5,7,8,10,39,40

Personal Digital Assistants: Utility and Challenges

PDAs are useful in guiding point-of-care decisions in diagnostics41,42 and pharmacotherapy4345 and they have the potential to reduce medical errors and improve patient outcomes.4649 At Vancouver General Hospital, clinical pharmacists use PDAs each day during routine patient care. The benefits obtained make the PDA an ideal device for the prospective collection of patient information.

In our study, we noted several advantages of PDAs over traditional retrospective, paper-based chart reviews. The real-time data collected via a PDA allowed a more complete capture of information, as the opportunity existed to clarify records and outcomes with health care providers without the need to interpret chart notes. The data-collection time was shortened significantly during point-of-care activities (4 minutes with a PDA vs. 28 minutes with retrospective chart review per patient case). Most important, DUE information can be reported and analyzed in a timely manner because the data are immediately available after the PDA information is synchronized to the central database.

Overall, the pharmacists in our study found PDAs to be effective data-collection tools that required minimal training and that did not hinder the delivery of routine care. Similarly, in a study of the use of PDAs to track treatment with broad-spectrum antibacterial drugs during routine care, Benson concluded that minimal training was required to use the devices; data collection was successful, with a minimal number of incomplete forms; and physicians accepted the additional workload.12

The major challenge that we encountered involved the participation of data collectors. All clinical pharmacists on inpatient wards were recruited and trained, but only 69% participated. Because pharmacists visit patients and dispense medications on a rotating basis, a possible cause of their lower rate of participation could have been their unfamiliarity with the study. Therefore, they might have been unaware of the ongoing study, in that training occurred 1 month before the data-collection period. To overcome this obstacle, training should be provided just before data collection and it should be reinforced throughout the data-collection period.

Wireless, automatic synchronization of patient information to the database was not possible with the Palm Pilot Tungsten E/E2 devices used in this study. We anticipate that data collection and transmission will be facilitated with the availability of more technologically advanced hand-held devices.

Based on our results, a PDA data-collection system, together with trained and motivated clinical pharmacists, can be used to prospectively and rapidly collect drug- usage information for analysis within an institution. Possible applications of this system include timely review of drug utilization after the introduction of a new medication, a new drug policy, or a drug safety alert. Such data-collection systems may be customtailored to other point-of-care devices, such as the Blackberry, iPhone, iPod Touch, or iPad.


Because our investigation took place in only one facility, the moxifloxacin DUE results might not be applicable to other institutions. Nevertheless, the evidence-based assessment criteria can be applied at other sites in order to review the appropriateness of moxifloxacin prescribing.

The assessment was performed over a period of 4 weeks; therefore, our findings might not represent moxifloxacin usage throughout the year. However, the study provides a cross-section of drug utilization at the time of data collection, which can be used to review current practice.

Assessment criteria were derived from evidence in the literature, and the “place of therapy” for moxifloxacin was determined based on local practices. Our intent was to limit moxifloxacin overuse outside of community-associated respiratory infections to prevent resistance.

Because of drug allergies and resistance to other antibiotics, moxifloxacin may have been considered appropriate first-line therapy for conditions that normally would have required an alternative treatment with moxifloxacin. This circumstance, however, was not considered in our study.

Finally, we did not evaluate the dosage or duration of therapy for appropriateness, because the usual dosage for moxifloxacin is standardized at 400 mg daily and the duration of use may vary greatly based on the patient’s clinical status.


Moxifloxacin use at Vancouver General Hospital appears to be concordant with evidence-based assessment criteria. Further opportunities to optimize the drug’s use exist, including medical staff education through academic detailing, in-services, patient-care rounds, and newsletters, as well as optimization of the pharmacist-managed IV-to-oral conversion service. PDAs are feasible data-collection tools that can be used during routine patient care to conduct DUEs. These devices offer advantages over paper-based data collection, and they are relatively easy to use.

Figures and Tables

Summary of patient data flow.

Percentage of moxifloxacin utilization according to assessment criteria (N = 132). AECB = acute exacerbations of chronic bronchitis; CAP = community-acquired pneumonia.“Other” includes empyema, malignant pleural effusion, postoperative pulmonary surgery, tuberculosis, intra-abdominal infections, acute bacterial sinusitis, and skin and skin-structure infections.

Clinical outcomes according to indication and assessment criteria (N = 129). Success indicates (1) complete resolution of signs and symptoms of infection; (2) clinically significant decrease in symptoms of infection; or (3) healthy upon discharge. Indeterminate indicates no evaluation possible because of insufficient information. Failure indicates (1) persistence or worsening of signs and symptoms of infection necessitating the initiation of an alternative antimicrobial therapy or (2) no significant remission of signs and symptoms (no improvement in baseline parameters). AECB = acute exacerbations of chronic bronchitis; CAP = community-acquired pneumonia; HAP = hospital-acquired pneumonia; Post-op = postoperative; SSSI = skin and skin-structure infections; TB = tuberculosis.

Utilization patterns according to level of evidence and prescribing service (N = 130). BMT = bone marrow transplantation; CV = cardiovascular; ENT = ears, nose, and throat; ICU = intensive-care unit; TB = tuberculosis.

Evidence-Based Assessment Criteria for Moxifloxacin

Indication Level of Evidencea Place in Therapyb
  • Acute exacerbation of chronic bronchitis
  • Community-acquired pneumonia
I First-line therapy
  • Acute bacterial sinusitis
  • Helicobacter pylori peptic ulcer disease
  • Intra-abdominal infections
  • Skin and skin-structure infections
I Alternative therapy
  • Bacterial meningitis
  • Tuberculosis
  • Hospital-acquired pneumonia
  • Q-fever pneumonia (Coxiella burnetii)
  • Ventilator-associated pneumonia

Level of Evidence (based on the grading system for ranking recommendations in clinical guidelines):

  • Level I: evidence from at least one properly randomized, controlled trial
  • Level II: evidence from at least one well-designed clinical trial without randomization; from cohort-controlled or case-controlled analytical studies (preferably from multiple centers); from multiple time-series studies; or from dramatic results in uncontrolled experiments
  • Level III: evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

Place in Therapy:

  • First-line therapy: moxifloxacin should be the agent of choice.
  • Alternative therapy: moxifloxacin is considered a therapeutic alternative when a first-line agent is documented to be contraindicated or inappropriate.

Demographic Characteristics

No. of patients 132

Age (years), median (range) 73 (20–100)

Sex, n (%)
  Male 71 (53.8)
  Female 61 (46.2)

Antibiotic allergy or intolerance, n (%)
  No known drug allergies 91 (68.9)
  Penicillin/cephalosporin 26 (19.7)
  Sulfonamide 15 (11.4)
  Macrolide 4 (3.0)
  Ciprofloxacin 3 (2.3)
  Clindamycin 3 (2.3)
  Tetracycline 2 (1.5)
  Acyclovir 1 (0.8)
  Bacitracin 1 (0.8)
  Metronidazole 1 (0.8)
  Quinine sulphate 1 (0.8)

Comorbidity, n (%)
  Respiratory disease (asthma, COPD) 40 (30.3)
  Immunocompromised state 37 (28.0)
  Hospitalized more than 48 hours before pneumonia 35 (26.5)
  None 24 (18.2)
  Diabetes mellitus 21 (15.9)
  Recent non-fluoroquinolone antibiotic use (within 3 months) 21 (15.9)
  Other concomitant infection 15 (11.4)
  Recent hospitalization 14 (10.6)
  Recent fluoroquinolone antibiotic use (within 3 months) 12 (9.1)
  Arrhythmia/antiarrhythmic drugs 9 (6.8)
  Chronic renal failure 6 (4.5)
  Ventilated ICU patient 6 (4.5)
  Seizure disorder (within 3 months) 3 (2.3)

Service, n (%)
  General medicine 50 (37.9)
  Respiratory 26 (19.7)
  General surgery 10 (7.8)
  Thoracic surgery 10 (7.8)
  Cardiovascular 7 (5.3)
  Orthopedics 6 (4.5)
  Bone marrow transplantation 3 (2.3)
  Neurology 3 (2.3)
  ICU 3 (2.3)
  Otolaryngology (ENT) 2 (1.5)
  Palliative care 2 (1.5)
  Tuberculosis 2 (1.5)
  Urology 2 (1.5)
  Trauma 2 (1.5)
  Nephrology 1 (0.8)
  Spine 1 (0.8)

COPD = chronic obstructive pulmonary disease; ENT = ears, nose, and throat; ICU = intensive-care unit.

Median Duration of Moxifloxacin Therapy

Indication Median Duration, (No. of Days, Range)

First-line therapy

  Acute exacerbations of chronic bronchitis 7 (2–16)
  Community-acquired pneumonia 7 (1–15)

Alternative therapy

  Empyema 8 (6–10)
  Hospital-acquired pneumonia 6 (2–14)
  Intra-abdominal infections 5
  Pleural effusion 8 (8–10)
  Postoperative pulmonary surgery 7
  Skin and skin-structure infections 8
  Sinusitis 6
  Tuberculosis 22 (16–28)

Results of a Utility Survey on Personal Digital Assistant (PDA) Devices (N = 9)

1 Strongly Disagree 2 3 4 5 Strongly Agree
Easy navigation through PDA program 11% 22% 67%
Study participation did not affect delivery of patient care 44% 45% 11%
Willing participation in future PDA-based data-collection studies 11% 33% 56%
Time (in minutes) <2 2–4 5–7 8–10 > 10
Average time (in minutes) to complete required data entry for one patient 11% 45% 44%
Author bio: 
Dr. Samilski is an Internal Medicine Resident, Faculty of Medicine, at the University of British Columbia in Vancouver, B.C., Canada. Dr. Lau is a Pharmacotherapeutic Specialist in Infectious Diseases, Pharmaceutical Sciences, at Vancouver General Hospital; a Clinical Associate Professor, Faculty of Pharmaceutical Sciences; and an Associate Member, Division of Infectious Diseases, Faculty of Medicine, at the university. Dr. Elbe is a Clinical Pharmacy Specialist in Child and Adolescent Psychiatry in the Department of Pharmacy at the Children’s and Women’s Health Centre of British Columbia in Vancouver and a Clinical Instructor, Faculty of Pharmaceutical Sciences, at the university. Dr. Aulakh is a Pharmacotherapeutic Specialist in Internal Medicine, Pharmaceutical Sciences, at Vancouver General Hospital, and a Clinical Instructor, Faculty of Pharmaceutical Sciences, at the university. Dr. Lun is Executive Director, Drug Intelligence Branch, Pharmaceutical Services Division, Ministry of Health Services, in Victoria, B.C.


  1. Keating GM, Scott LJ. Moxifloxacin: A review of its use in the management of bacterial infections. Drugs 2004;64;(20):2347–2377.
  2. Avelox Product Monograph Toronto, Ontario, Canada: Bayer Health Canada, Inc. February 52007;
  3. Speirs GE, Fenelon LE, Reeves DS, et al. An audit of ciprofloxacin use in a district general hospital. J Antimicrob Chemother 1995;36:201–207.
  4. Lacombe K, Cariou S, Tilleul P, et al. Optimizing fluoroquinolone utilization in a public hospital: A prospective study of educational intervention. Eur J Clin Microbiol Infect Dis 2005;24:6–11.
  5. Pulcini C, Mondain V, Lieutier F, et al. Fluoroquinolone prescriptions in a teaching hospital: A prospective audit. Scand J Infect Dis 2007;39:1013–1017.
  6. Lautenbach E, Larosa LA, Kasbekar N, et al. Fluoroquinolone utilization in the emergency departments of academic medical centers. Arch Intern Med 2003;163:601–605.
  7. Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;188;(3):259–268.
  8. Hammerman A, Greenberg A, Yinnon AM. Drug use evaluation of ciprofloxacin: Impact of educational efforts on appropriateness of use. J Clin Pharm Ther 1997;22:415–420.
  9. Belliveau PP, Brennan WP, Rothman AL. Levofloxacin use at an academic teaching institution. Am J Health Syst Pharm 2000;57:1791–1793.
  10. Méan M, Pavese P, Vittoz JP, et al. Prospective assessment of fluoroquinolone use in a teaching hospital. Eur J Clin Microbiol Infect Dis 2006;25;(12):757–763.
  11. 1996 Comprehensive Accreditation Manual for Hospitals Oakbrook Terrace, Ill: Joint Commission on Accreditation of Healthcare Organizations. 1996;
  12. Benson K. Electronic data collection tools for quality improvement: Antibiotic utilization project. AMIA Annu Symp Proc 2003;788
  13. Scottish Intercollegiate Guidelines Network (SIGN). Search filters Available at: Accessed March 29, 2012.
  14. Kish MA. ISDA [Infectious Diseases Society of America] Guidelines. Guide to development of practice guidelines. Clin Infect Dis 2001;32;(15):851–854.
  15. Schaberg T, Ballin I, Huchon G, et al. A multinational, multi-centre, non-blinded, randomized study of moxifloxacin oral tablets compared with amoxicillin–clavulanate oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001;29:314–328.
  16. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953–956.
  17. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2004;23:129–137.
  18. Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 2000;94:18–27.
  19. Wilson R, Kubin R, Ballin I, et al. Five-day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501–513.
  20. Jardim JR, Rico G, de la Roza C, et al. A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: Results of a multicenter clinical trial. Arch Bronconeumol 2003;39:387–393.
  21. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185–195.
  22. Lode H, Grossman C, Choudhri S, et al. Sequential IV/PO moxifloxacin in the treatment of patients with severe community-acquired pneumonia. Respir Med 2003;97:1134–1142.
  23. File TM, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Today’s Ther Trends 2001;19:251–270.
  24. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Infect Med 1999;16:748–763.
  25. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997;112:310S–313S.
  26. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347–382.
  27. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405–1433.
  28. ATS/IDSA [American Thoracic Society/Infectious Disease Society of America] Guideline Committee. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
  29. Gehano P, Berche P, Perrin A. Moxifloxacin in the treatment of acute maxillary sinusitis after first-line treatment failure and acute sinusitis with high-risk complications. J Int Med Res 2003;31:434–447.
  30. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000;94:337–344.
  31. Burke T, Villanueva C, MarianoHJret al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther 1999;21;(10):1664–1677.
  32. Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000;54:497–503.
  33. Giordano P, Song B, Pertel P, et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin–tazobactam followed by oral amoxicillin–clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005;26:357–365.
  34. Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillin–tazobactam and amoxicillin–clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006;244;(2):204–211.
  35. Snow V, Mottur-Pilson C, Hickner J. Principles of appropriate antibiotic use for acute sinusitis in adults. Ann Intern Med 2001;134:495–497.
  36. Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis Edmonton, Alberta, Canada: Alberta Clinical Practice Guidelines Program, Alberta Medical Association. November 2001;Available at:$File/acute_sinusitus.pdf. Accessed May 2, 2011.
  37. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373–1406.
  38. Solomkin J, Mazuski J, Baron E, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997–1005.
  39. Ho B, Lau T, Balen R, et al. The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: A pre-and post-intervention study. BMC Health Serv Res 2005;5:48
  40. Frighetto L. New drugs and drug products: Parenteral ciprofloxacin (Cipro IV). In: Shalansky K. Drugs and Therapeutics Newsletter Vancouver, B.C., Canada: Vancouver Hospital and Health Sciences Centre. 1992;
  41. Bogusevicius A, Maleckas A, Pundzius J, Skaudickas D. Prospective randomized trial of computer-aided diagnosis and contrast radiography in acute small bowel obstruction. Eur J Surg 2002;168:78–83.
  42. Selker HP, Beshansky JR, Griffith JL, et al. Use of the acute cardiac ischemia time-insensitive predictive instrument (ACITIPI) to assist with the triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia: A multicenter controlled clinical trial. Ann Intern Med 1998;129:845–855.
  43. Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998;280:1311–1316.
  44. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001;286:2839–2844.
  45. Potts AL, Barr FE, Gregory DF, et al. Computerized physician order entry and medication errors in a pediatric critical care unit. Pediatrics 2004;113:59–63.
  46. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: A systematic review. JAMA 2005;293:1223–1238.
  47. Payne TH. Computer decision support systems. Chest 2000;118:47S–52S.
  48. Sim I, Gorman P, Greenes RA, et al. Clinical decision support systems for the practice of evidence-based medicine. J Am Med Inform Assoc 2001;8:527–534.
  49. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: A systematic review. Arch Intern Med 2003;163:1409–1416.